Anti-Integrins, Anti-Interleukin 12/23p40, and JAK Inhibitors for the Inflammatory Bowel Disease Treatment

2020 ◽  
Author(s):  
Karine Mariane Steigleder ◽  
Fernando Lopes Ponte Neto ◽  
Cristiane Kibune Nagasako ◽  
Raquel Franco Leal
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Interleukin 12 ◽  
Jak Inhibitors ◽  
Disease Treatment ◽  
Inflammatory Bowel

scholarly journals The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment

2021 ◽  
Vol 22 (21) ◽  
pp. 11322
Author(s):  
Jin-Woo Kim ◽  
Su-Young Kim
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Kinase Inhibitors ◽  
Significant Proportion ◽  
Janus Kinase ◽  
Response To Treatment ◽  
Interleukin 12 ◽  
Disease Treatment ◽  
Janus Kinase Inhibitors ◽  
Inflammatory Bowel

For a significant proportion of patients with inflammatory bowel disease (IBD), primary non-response and secondary loss of response to treatment remain significant issues. Anti-tumor necrosis factor therapies have been licensed for use in IBD. Other disease-related pathways have been targeted as well, including the interleukin 12/23 axis and lymphocyte tracking. However, the need for parenteral administration and the associated costs of dispensing and monitoring all biologics remain a burden on healthcare systems and patients. Janus kinase inhibitors are small-molecule drugs that can be administered orally and are relatively inexpensive, thus offering an additional option for treating IBD. They have been shown to be effective in patients with ulcerative colitis (UC), but they are less effective in those with Crohn’s disease (CD). Nonetheless, given the immune-system-based mechanism of these drugs, their safety profile remains a cause for concern. This article provides an overview of Janus kinase (JAK) inhibitors and new trends in the treatment of IBD.

Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease

2018 ◽  
Vol 30 (8) ◽  
pp. 854-860 ◽  
Author(s):  
Kamolyut Lapumnuaypol ◽  
Napatt Kanjanahattakij ◽  
David Pisarcik ◽  
Charat Thongprayoon ◽  
Karn Wijarnpreecha ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Bowel Disease ◽  
Fatty Liver Disease ◽  
Disease Treatment ◽  
Nonalcoholic Fatty Liver ◽  
Inflammatory Bowel

Orally administrated nucleotide-delivery particles from microfluidics for inflammatory bowel disease treatment

2021 ◽  
Vol 25 ◽  
pp. 101231
Author(s):  
Jingjing Gan ◽  
Yuxiao Liu ◽  
Lingyu Sun ◽  
Wenjuan Ma ◽  
Guopu Chen ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Disease Treatment ◽  
Inflammatory Bowel

scholarly journals Controlling Gut Inflammation by Restoring Anti-Inflammatory Pathways in Inflammatory Bowel Disease

Cells ◽  
2019 ◽  
Vol 8 (5) ◽  
pp. 397 ◽  
Author(s):  
Paolo Giuffrida ◽  
Sara Cococcia ◽  
Mariangela Delliponti ◽  
Marco Vincenzo Lenti ◽  
Antonio Di Sabatino
Keyword(s):  
Inflammatory Bowel Disease ◽  
Side Effects ◽  
Bowel Disease ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Interleukin 10 ◽  
Interleukin 12 ◽  
Inflammatory Pathways ◽  
Inflammatory Bowel ◽  
Anti Inflammatory

Inflammatory bowel disease (IBD) is caused by a dysregulated immune response against normal components of the intestinal microflora combined with defective functioning of anti-inflammatory pathways. Currently, all therapies approved for IBD manipulate the immune system by inhibiting pro-inflammatory mechanisms, such as tumor necrosis factor-α, gut-homing α4β7 integrin, interleukin-12/interleukin-23, and Janus kinases. However, some IBD patients are non-responders to these drugs, which are also associated with serious side effects. Thus, it has been hypothesized that therapies aimed at restoring anti-inflammatory signals, by exploiting the tolerogenic potential of cytokines (interleukin-10, transforming growth factor-β, granulocyte macrophage colony-stimulating factor), immune cells (regulatory T cells, tolerogenic dendritic cells), or mesenchymal stem cells, might offer promising results in terms of clinical efficacy with fewer side effects. In this review, we provide new insights into putative novel treatments aimed at restoring anti-inflammatory signaling pathways in IBD.

Interleukin-12 Antagonists as New Therapeutic Agents in Inflammatory Bowel Disease

Pathobiology ◽  
2002 ◽  
Vol 70 (3) ◽  
pp. 177-183 ◽  
Author(s):  
Carsten Schmidt ◽  
Thomas Marth ◽  
Bianca M. Wittig ◽  
Andreas Hombach ◽  
Hinrich Abken ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Therapeutic Agents ◽  
Interleukin 12 ◽  
Inflammatory Bowel

Coatless alginate pellets as sustained-release drug carrier for inflammatory bowel disease treatment

2016 ◽  
Vol 152 ◽  
pp. 370-381 ◽  
Author(s):  
Siti Hajar Md Ramli ◽  
Tin Wui Wong ◽  
Idanawati Naharudin ◽  
Anirbandeep Bose
Keyword(s):  
Inflammatory Bowel Disease ◽  
Sustained Release ◽  
Bowel Disease ◽  
Drug Carrier ◽  
Disease Treatment ◽  
Release Drug ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document